Loading...
•
Sep 30
BioNano Q3 2025 Earnings Report
Bionano reported a narrower net loss for Q3 2025 alongside a 21% increase in revenue year-over-year, supported by higher instrument and consumables sales.
Key Takeaways
Bionano delivered improved results in Q3 2025, with revenue growth and significantly lower operating expenses contributing to a reduced net loss. The company also reported higher flowcell sales and an increase in installed systems, indicating ongoing adoption of its optical genome mapping platform.
Revenue reached $7.37 million, up from $6.07 million in Q3 2024.
Net loss narrowed to $8.5 million, a significant improvement from $44.2 million in the prior year quarter.
Operating expenses dropped 66% year-over-year, demonstrating strong cost discipline.
Flowcell shipments increased 7% YoY to 8,390, while the installed base rose to 384 systems.
BioNano
BioNano
BioNano Revenue by Segment
Revenue by Segment
Product Revenue
CapyFin.comService and Other Revenue
CapyFin.com Forward Guidance
Bionano reiterated its full-year revenue guidance and initiated Q4 expectations, projecting modest sequential growth and more than 25 OGM system installations for the year.
Positive Outlook
- Q4 2025 revenue guidance set between $7.5M and $7.9M
- Full-year 2025 revenue outlook remains $26M to $30M
- Instrument installations expected to exceed 25 for FY25
- New CMS CPT code determination for OGM supports reimbursement pathway
- Strong publication momentum reinforces clinical and research utility of OGM
Challenges Ahead
- Company remains unprofitable with negative operating income
- Cash and cash equivalents dropped to $3.1 million
- Dependency on additional financing to sustain operations
- Macroeconomic conditions and global conflicts could pressure growth
- Ongoing restructuring and cost cuts underscore financial strain
Revenue & Expenses
Visualization of income flow from segment revenue to net income